NASDAQ$ZLAB
Zai Lab Limited-ADR · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Zai Lab's Q4 2023 financial results were announced, showcasing growth in product revenue and strategic progress.
Zai Lab reported a full-year 2023 product revenue of $266.7 million, representing a 25% year-over-year growth. The company highlighted the successful launch of VYVGART in China and its inclusion in the NRDL. Zai Lab is focused on achieving corporate profitability by the end of 2025.
- Total product revenue reached $266.7 million for full-year 2023, a 25% increase year-over-year.
- VYVGART was successfully launched in China in September 2023 and added to the NRDL effective January 1, 2024.
- The company estimates nearly 1,000 patients were treated with VYVGART through Q4 2023.
- Zai Lab had a strong cash position of $807.6 million as of December 31, 2023.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$65.8M
Revenue by segment
Zai Lab · $52M total across 3 segments · Q3 2023
- ZEJULA$41.6M+6.1%80.0%
- NUZYRA$5.5M+266.7%10.6%
- VYVGART franchise$4.9M—9.4%
Forward guidance
Zai Lab will focus on commercial execution, clinical data and regulatory actions, and clinical development in 2024.
Tailwinds
- Drive VYVGART ramp-up in gMG in its first year of NRDL inclusion and increase access via hospital listing
- Maintain ZEJULA leadership position in ovarian cancer in China
- Continue to grow supplemental insurance coverage for OPTUNE GIO® in glioblastoma (GBM)
- Successfully launch additional products (up to 3) from our innovative pipeline
- Potential NMPA approval of the NDA in locally advanced or metastatic ROS1-positive NSCLC.
Headwinds
- Risks related to doing business in China
- Uncertainties in clinical development programs and related clinical trials
- Delays in regulatory discussions, submissions, filings, and approvals
- The company's ability to obtain funding for its operations and business initiatives
- Ability to successfully commercialize and generate revenue from approved products
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro